Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof

A crystal form of mono-p-toluenesulfonate of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethylphosphine oxide or a hydrate thereof, wherein the X-ray powder diffraction pattern has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 13.2°±0.2° and 21.8°±0.2°;

• further, the X-ray powder diffraction pattern has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 21.8°±0.2° and 22.6°±0.2°;
• further, the X-ray powder diffraction pattern has diffraction peaks at 2θ of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 13.2°±0.2°, 15.2°±0.2°, 18.0°+0.2°, 18.6°+0.2°, 18.7°+0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.8°±0.2°, 22.6°±0.2° and 29.4°±0.2°;
• further, the X-ray powder diffraction pattern has diffraction peaks at 2° of 6.0°±0.2°, 6.3°±0.2°, 10.5°±0.2°, 11.5°±0.2°, 12.3°±0.2°, 12.4°±0.2°, 12.6°±0.2°, 13.2°±0.2°, 14.10°±0.2°, 15.2°±0.2°, 15.9°±0.2°, 16.7°±0.2°, 17.1°±0.2°, 18.0°±0.2°, 18.6°±0.2°, 18.7°±0.2°, 19.0°±0.2°, 19.4°±0.2°, 19.7°±0.2°, 21.1°±0.2°, 21.8°±0.2°, 22.6°±0.2°, 23.3°±0.2°, 23.7°±0.2°, 24.1°±0.2°, 24.4°±0.2°, 24.7°±0.2°, 25.1°±0.2°, 26.2°±0.2°, 26.6°±0.2°, 27.0°±0.2°, 27.7°±0.2°, 28.0°±0.2°, 28.3°±0.2°, 28.7°±0.2°, 28.8°±0.2°, 29.4°±0.2°, 30.2°±0.2° and 33.9°±0.02°.